Log in to save to my catalogue

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting...

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting...

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bba37d73a22040bf8e933a5ac92c20e4

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review

About this item

Full title

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review

Publisher

England: Hindawi

Journal title

Cardiovascular therapeutics, 2022-02, Vol.2022, p.8129513-6

Language

English

Formats

Publication information

Publisher

England: Hindawi

More information

Scope and Contents

Contents

As dyslipidemias remain one of the main risk factors for developing cardiovascular disease, the question of maintaining optimal lipid levels with pharmacotherapy remains a subject of interest worldwide. In contrast to conventional pharmacotherapy, human monoclonal antibodies directed against proprotein convertase subtilisin/kexin type 9 (PSCK9) and...

Alternative Titles

Full title

Advantages and Disadvantages of Inclisiran: A Small Interfering Ribonucleic Acid Molecule Targeting PCSK9—A Narrative Review

Authors, Artists and Contributors

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_doaj_primary_oai_doaj_org_article_bba37d73a22040bf8e933a5ac92c20e4

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_bba37d73a22040bf8e933a5ac92c20e4

Other Identifiers

ISSN

1755-5914

E-ISSN

1755-5922

DOI

10.1155/2022/8129513

How to access this item